Get the Stockscreener App
4.1569
2.42%
0.0169
Clene Inc stock is traded at $4.1569, with a volume of 55,484.
It is up +2.42% in the last 24 hours and down -28.38% over the past month.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
See More
Previous Close:
$4.14
Open:
$4.14
24h Volume:
55,484
Relative Volume:
0.60
Market Cap:
$53.67M
Revenue:
$134.00K
Net Income/Loss:
$-33.51M
P/E Ratio:
-1.296
EPS:
-3.2074
Net Cash Flow:
$-18.15M
1W Performance:
-17.83%
1M Performance:
-28.38%
6M Performance:
+0.47%
1Y Performance:
+17.13%
1-Day Range:
$4.10
$4.40
1-Week Range:
$3.955
$5.11
52-Week Range:
$3.64
$13.50
Clene Inc Stock (CLNN) Company Profile
Name
Clene Inc
Sector
Industry
Phone
801-676-9695
Address
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
4.20 | 52.90M | 134.00K | -33.51M | -18.15M | -3.2074 |
VRTX
Vertex Pharmaceuticals Inc
|
515.07 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.61 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.05 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.65 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
361.72 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-18-22 | Initiated | H.C. Wainwright | Buy |
| May-02-22 | Initiated | Canaccord Genuity | Buy |
| Sep-28-21 | Initiated | Oppenheimer | Outperform |
Clene Inc Stock (CLNN) Latest News
Clene to Present at the Emerging Growth Conference - marketscreener.com
Clene schedules a 3:10 p.m. webcast—what will it cover? - Stock Titan
Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com
Clene (NASDAQ:CLNN): Why Is Evidence And Funding in Focus Today? - kalkinemedia.com
Clene (NASDAQ:CLNN): Why Is Clinical Evidence in Focus Today? - Kalkine Media
CLNN Looks 375.9% Overvalued on GF Value™ - GuruFocus
CLNN Stock Rises 8% – Here’s What The FDA Update Means For Clene’s ALS Treatment - Stocktwits
Clene (NASDAQ:CLNN) Announces Quarterly Earnings Results, Misses Estimates By $0.71 EPS - marketbeat.com
Clene Releases Q2 2026 Financial Results - AlphaStreet
Vivo Opportunity entities disclose 9.99% Clene Inc. (CLNN) stake via warrants - Stock Titan
Clene Inc. (CLNN) grants 4,872 stock options to director Alison Mosca - Stock Titan
Clene Inc. (CLNN) grants director Arjun Desai 3,674 options at $4.19 strike - Stock Titan
Clene Inc. (CLNN) director receives 6,230 stock options at $4.19 strike - Stock Titan
Clene Inc. (CLNN) awards director Shalom Jacobovitz 4,752 stock options at $4.19 - Stock Titan
Clene Inc. (CLNN) director receives 3,514 stock options vesting immediately at $4.19 - Stock Titan
Clene Inc. (CLNN) director granted 3,514 stock options at $4.19 strike - Stock Titan
Clene Q2 FY26 net loss widens 81% to $13.42 million - Bitget
Clene Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Clene Inc. (CLNN) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Form 8K Clene Inc. For: 14 August By Investing.com - Investing.com Canada
Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights - The Manila Times
Clene Inc. (NASDAQ: CLNN) widens Q2 loss while preparing accelerated ALS NDA - Stock Titan
ALS patients whose nerve marker declined or stabilized lived longer, Clene says - Stock Titan
CLNN: Net loss widened to $13.4M in Q2 2026, with ongoing funding concerns and rising R&D costs - TradingView
Clene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
CLNN Q2'26 Earnings: EPS estimate is (0.37) USD - TradingView
Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS - MarketBeat
Clene Nanomedicine at canaccord growth conference: FDA path in focus By Investing.com - Investing.com Canada
Clene Inc. (CLNN) holder Ugwumba exits, reports 0% beneficial stake - Stock Titan
Clene Inc. (NASDAQ:CLNN) Receives Average Recommendation of "Moderate Buy" from Analysts - marketbeat.com
Clene reports survival benefit in ALS patients with NfL response By Investing.com - Investing.com UK
Empery Asset Management, LP Buys Clene Inc (CLNN) -- Shares Look 486% Overvalued on GF Value - GuruFocus
Clene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval - Investing News Network
Clene Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Clene reports survival benefit in ALS patients with NfL response - Investing.com
Form 8K Clene Inc. For: 10 August By Investing.com - Investing.com Australia
Clene (CLNN) ties CNM-Au8 ALS survival gains to NfL biomarker for planned NDA - Stock Titan
Clene ALS Trial Links Nerve-Injury Marker to Nearly 6-Month Survival Gain - Stock Titan
CLNN Q2'26 Earnings: revenue estimate is 61.00K USD - TradingView
Clene Inc. (CLNN) Stock News Today - TradingKey
Clene Inc. (CLNN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Clene Inc. (CLNN) insider relinquishes 799,358 warrant rights in fund shift - Stock Titan
Clene (CLNN) Expected to Announce Quarterly Earnings on Thursday - marketbeat.com
Empery Asset Management (CLNN) discloses 7.17% beneficial stake in Clene - Stock Titan
Clene Inc. (CLNN) Institutional Confidence - TradingKey
Nanotechnology Stocks To ConsiderJuly 30th - marketbeat.com
Clene to Present at The Canaccord 46th Annual Growth Conference - The Manila Times
Nanotechnology Stocks To Watch TodayJuly 29th - marketbeat.com
Best Nanotechnology Stocks Worth WatchingJuly 27th - MarketBeat
Clene Inc. (CLNN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CLNN|Clene Inc.|Price:5.410|Chg%:+0.020 - TradingKey
Clene Inc Stock (CLNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Clene Inc Stock (CLNN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ugwumba Chidozie | 10% Owner |
May 11 '26 |
Sale |
6.75 |
22,177 |
149,695 |
176,713 |
2.67%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):